Trials / Withdrawn
WithdrawnNCT03129074
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
A Phase 2, Single Arm Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as First-line Systemic Therapy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- ASLAN Pharmaceuticals · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the efficacy of varlitinib in combination with capecitabine as measured by objective response rate (ORR) assessed by independent central review (ICR), based on RECIST v1.1 criteria.
Detailed description
Also to explore the role of biomarkers as predictors of response and clinical benefit with varlitinib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Varlitinib | everyday |
| DRUG | Capecitabine | from Day 1 to Day 14 followed by 7-day of rest period, every 21 days. |
Timeline
- Start date
- 2018-05-01
- Primary completion
- 2020-03-01
- Completion
- 2020-09-01
- First posted
- 2017-04-26
- Last updated
- 2018-05-23
Source: ClinicalTrials.gov record NCT03129074. Inclusion in this directory is not an endorsement.